PRQR News and Press, ProQR Therapeutics N.V. From 03/13/24

Preclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GALT1 anticipated in 2024, building further momentum toward the clinic Accelerated development of Axiomer™ for CNS applications via...

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has successfully defended against an opposition filed in Japan against a pat...

Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human primates (NHPs) and mice Functional effect demonstrated in mice in vivo via modulation of ANGPLT3 protein properties leading to favorable increase in LPL enzymatic a...

2024-01-18 13:35:16 ET More on Mid-day movers & stocks. Phunware, Inc. (PHUN) Q3 2023 Earnings Call Transcript Jasper Therapeutics to effect 1-for-10 reverse stock split Phunware Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Jasper Thera...

2024-01-17 12:43:14 ET Gainers: Airspan Networks Holdings ( MIMO ) +360% . LQR House ( LQR ) +33% . Safety Shot ( SHOT ) +25% . MAIA Biotechnology ( MAIA ) +27% . ProQR Therapeutics ( PRQR ) +27% . Bullfrog AI Holdings BFRG ...

Partnership focused on utilizing Axiomer ™ to develop editing oligonucleotides targeting an underlying genetic variant that causes Rett syndrome Collaboration expands ProQR’s commitment to advance the development of therapies for central nervous system diseases LEIDEN,...

Divestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome Agreement provides ProQR with initial payment of €8M and up to €165M in earn-out payments, as well as potentia...

ProQR Therapeutics N.V. (PRQR) is expected to report $-0.06 for Q3 2023

2023-11-07 08:01:38 ET More on ProQR Seeking Alpha’s Quant Rating on ProQR Historical earnings data for ProQR Financial information for ProQR For further details see: ProQR GAAP EPS of -€0.07, revenue of €1.37M

Continued advancement of platform and initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1 Further strengthened leading intellectual property (IP) position with issuance of new patent in the United States and...